Can the HPV vaccine protect stem cell transplant patients?
NCT ID NCT03023631
First seen Nov 18, 2025 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This study tests whether the Gardasil 9 vaccine can help stem cell transplant patients build immunity against HPV. About 48 adults who had a stem cell transplant for blood cancer will receive the vaccine. Researchers will measure antibody levels to see if the vaccine works in these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gardasil 9 (HPV vaccine)
What this could lead to
If successful, this could show that the HPV vaccine works in stem cell transplant patients, helping prevent HPV-related cancers in this vulnerable group.
What could go wrong
This is a small, single-center study (48 people) with no placebo group. The immune response may be weaker in transplant patients, and the vaccine may not prevent infection or cancer long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.